Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice
- 1 July 2007
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 18 (7) , 2116-2124
- https://doi.org/10.1681/asn.2006121385
Abstract
Fibroblastic growth factor 23 (FGF23) regulates renal phosphate reabsorption and 1α-hydroxylase activity. Ablation of FGF23 results in elevated serum phosphate, calcium, and 1,25-dihydroxyvitamin D3 [1,25(OH)2D] levels; vascular calcifications; and early death. For determination of the independent roles of hyperphosphatemia and excess vitamin D activity on the observed phenotypic abnormalities, FGF23 null mice were fed a phosphate- or vitamin D–deficient diet. The phosphate-deficient diet corrected the hyperphosphatemia, prevented vascular calcifications, and rescued the lethal phenotype in FGF23 null mice, despite persistent elevations of serum 1,25(OH)2D and calcium levels. This suggests that hyperphosphatemia, rather than excessive vitamin D activity, is the major stimulus for vascular calcifications and contributes to the increased mortality in the FGF23-null mouse model. In contrast, the vitamin D–deficient diet failed to correct either the hyperphosphatemia or the vascular calcifications in FGF23 null mice, indicating that FGF23 independently regulates renal phosphate excretion and that elevations in 1,25(OH)2D and calcium are not sufficient to induce vascular calcifications in the absence of hyperphosphatemia. The vitamin D–deficient diet also improved survival in FGF23 null mice in association with normalization of 1,25(OH)2D and calcium levels and despite persistent hyperphosphatemia and vascular calcifications, indicating that excessive vitamin D activity can also have adverse effects in the presence of hyperphosphatemia and absence of FGF23. Understanding the independent and context-dependent interactions between hyperphosphatemia and excessive vitamin D activity, as well as vascular calcifications and mortality in FGF23 null mice, may ultimately provide important insights into the management of clinical disorders of hyperphosphatemia and excess vitamin D activity.Keywords
This publication has 41 references indexed in Scilit:
- Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient miceMatrix Biology, 2007
- Genetic Ablation of Vitamin D Activation Pathway Reverses Biochemical and Skeletal Anomalies in Fgf-23-Null AnimalsThe American Journal of Pathology, 2006
- Mortality risk among hemodialysis patients receiving different vitamin D analogsKidney International, 2006
- Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patientsKidney International, 2006
- Premature aging‐like phenotype in fibroblast growth factor 23 null mice is a vitamin D‐mediated processThe FASEB Journal, 2006
- Role of Matrix Extracellular Phosphoglycoprotein in the Pathogenesis of X-Linked HypophosphatemiaJournal of the American Society of Nephrology, 2005
- Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient miceMatrix Biology, 2004
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004
- Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteersKidney International, 2003
- Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidismKidney International, 2003